Perhaps not as immediately fresh and groovy as the breakthrough commercial successes of Good News For People Who Love Bad News or We Were Dead Before the Ship Even Sank, Modest Mouse’s latest effort, ...

On “Remember Yourself,” a elegiac, artfully shambling highlight from the new Modest Mouse album, Isaac Brock gives us lines that might as well as advertising copy for the record: “Try to maintain an ...

Like any indie institution worth their salt, Modest Mouse deals in big feelings. Isaac Brock’s rhythmic yawp emphasizes sheer size, trailer-dotted geographical expanse of the American west and ...

On their first independent album in nearly 30 years, the Pacific Northwest legends ponder endurance and mortality as they abandon the polish of recent releases for a looser, no-filter approach. No ...

Modest Mouse frontman Isaac Brock has spoken to NME about the Portland indie heroes’ new album ‘An Eraser and a Maze’, as well as the tragic death of founding drummer Jeremiah Green. The album is the ...

Java developers absolutely must learn Maven. Maven is the most popular and pervasive build tool in the Java world. Even if you don't use Maven directly, alternatives such as Gradle, Jenkins or Ivy ...

DETROIT (WXYZ) — The Michigan Science Center said a new life-sized cardboard maze is set to open next week that is inspired by Detroit landmarks. According to the ...

A Canadian who has worked in the gaming industry for over two decades, Beck grew up on games such as Final Fantasy and Super Mario Bros. He specalizes in roleplaying games, but covers titles in almost ...

Nahda Nabiilah is a writer and editor from Indonesia. She has always loved writing and playing games, so one day she decided to combine the two. Most of the time, writing gaming guides is a blast for ...

KNOXVILLE, Tenn. (WATE) —After sixteen years, VFL Bobby Maze still thinks about the game every week. “It haunted me,” he said. “It feels like it was yesterday.” In 2010, Maze’s senior year, the Vols ...

Maze Therapeutics leverages its Compass platform to translate human genetic insights into de-risked, high-probability drug candidates. MZE829 targets APOL1-mediated kidney disease with a dual ...